{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:34:57Z","timestamp":1793738097284,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.seizure.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T22:12:29Z","timestamp":1436825549000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["The adverse event profile of levetiracetam: A meta-analysis on children and adults"],"prefix":"10.1016","volume":"31","author":[{"given":"Alberto","family":"Verrotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Prezioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Chiarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2015.07.004_bib0290","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.seizure.2015.07.004_bib0295","first-page":"63","article-title":"Adverse effects of anticonvulsant drugs\u2014a critical review","volume":"5","author":"Beghi","year":"1986","journal-title":"Adverse Drug React Acute Poisoning Rev"},{"key":"10.1016\/j.seizure.2015.07.004_bib0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2015.07.004_bib0305","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.07.004_bib0310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2015.07.004_bib0315","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bcp.12083","article-title":"Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials","volume":"76","author":"Bodalia","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0320","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/14740338.3.5.415","article-title":"Levetiracetam safety profiles and tolerability in epilepsy patients","volume":"3","author":"Briggs","year":"2004","journal-title":"Expert Opin Drug Safe"},{"key":"10.1016\/j.seizure.2015.07.004_bib0325","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1528-1157.2000.tb00255.x","article-title":"Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group","volume":"41","author":"Cramer","year":"2000","journal-title":"Epilepsia"},{"issue":"January","key":"10.1016\/j.seizure.2015.07.004_bib0330","article-title":"Mechanisms of levetiracetam in the control of status epilepticus and epilepsy","author":"Deshpande","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0335","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNF.0b013E31807A32C6","article-title":"Levetiracetam is not effective for essential tremor","volume":"30","author":"Elble","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0340","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/j.1532-2149.2011.00073.x","article-title":"A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis","volume":"16","author":"Falah","year":"2012","journal-title":"Eur J Pain"},{"key":"10.1016\/j.seizure.2015.07.004_bib0345","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients","volume":"36","author":"Fertig","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.seizure.2015.07.004_bib0350","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sc.2009.55","article-title":"Levetiracetam in spinal cord injury pain: a randomized controlled trial","volume":"47","author":"Finnerup","year":"2009","journal-title":"Spinal Cord"},{"key":"10.1016\/j.seizure.2015.07.004_bib0355","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2015.07.004_bib0360","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.07.004_bib0365","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2015.07.004_bib0370","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/mds.20147","article-title":"Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor","volume":"19","author":"Handforth","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.seizure.2015.07.004_bib0375","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejpain.2010.11.007","article-title":"The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial","volume":"15","author":"Holbech","year":"2011","journal-title":"Eur J Pain"},{"key":"10.1016\/j.seizure.2015.07.004_bib0380","series-title":"IBM SPSS statistics for windows, version 19.0","author":"IBM Corp","year":"2010"},{"key":"10.1016\/j.seizure.2015.07.004_bib0385","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1684\/epd.2013.0599","article-title":"The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre","volume":"15","author":"Kang","year":"2013","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2015.07.004_bib0390","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0395","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1017\/S0317167100011902","article-title":"Meta-analysis of randomized trials on first line and adjunctive levetiracetam","volume":"38","author":"Lo","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.seizure.2015.07.004_bib0400","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2015.07.004_bib0405","first-page":"CD001901","article-title":"Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review","volume":"9","author":"Mbizvo","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2015.07.004_bib0410","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.07.004_bib0415","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000159956.87511.67","article-title":"Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy","volume":"28","author":"Otoul","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0420","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.seizure.2015.07.004_bib0425","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0430","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.07.004_bib0435","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0440","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1167.2008.01981.x","article-title":"Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures","volume":"50","author":"Pi\u00f1a-Garza","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0445","first-page":"CD005612","article-title":"Pregabalin add-on for drug-resistant partial epilepsy","volume":"3","author":"Pulman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2015.07.004_bib0450","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4088\/JCP.09m05659gre","article-title":"Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Saricicek","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.seizure.2015.07.004_bib0455","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.25.9.3639-3647.2005","article-title":"Targeted disruption of Tgif, the mouse ortholog of a human holoprosencephaly gene, does not result in holoprosencephaly in mice","author":"Shen","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0460","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0465","series-title":"Spec issue 29th int epilepsy congr Rome, 52","first-page":"120","article-title":"Adverse events of antiepileptic drugs across indications: can randomized controlled trials data from non-epilepsy indications be included in meta-analysis for AEDs used in epilepsy?","author":"Shukralla","year":"2001"},{"key":"10.1016\/j.seizure.2015.07.004_bib0470","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/mds.23355","article-title":"Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease","volume":"26","author":"Stathis","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.seizure.2015.07.004_bib0475","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08m04949gre","article-title":"Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial","volume":"71","author":"Stein","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.seizure.2015.07.004_bib0480","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00372.x","article-title":"Efficacy and safety of levetiracetam (up to 2000 mg\/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study","volume":"47","author":"Tsai","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0485","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1592\/phco.28.3.393","article-title":"Rapid dosage titration of levetiracetam in children","volume":"28","author":"Vaisleib","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.seizure.2015.07.004_bib0490","first-page":"297","article-title":"The adverse event profile of zonisamide: a meta-analysis","volume":"128","author":"Verrotti","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2015.07.004_bib0495","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1468-1331.2008.02206.x","article-title":"Effect of levetiracetam on the postmastectomy pain syndrome","volume":"15","author":"Vilholm","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0500","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-010-0472-x","article-title":"Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"117","author":"Wolz","year":"2010","journal-title":"J Neural Transm"},{"key":"10.1016\/j.seizure.2015.07.004_bib0505","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrneurol.2012.184","article-title":"Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signalling","volume":"8","author":"Wood","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0510","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","article-title":"Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Woods","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.seizure.2015.07.004_bib0515","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1528-1167.2008.01729.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures","volume":"50","author":"Wu","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0520","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000197109","article-title":"Efficacy and safety of levetiracetam (3,000 mg\/day) as an adjunctive therapy in Chinese patients with refractory partial seizures","volume":"61","author":"Xiao","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0525","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/epi.12679","article-title":"Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial","volume":"55","author":"Zaccara","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0530","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","article-title":"Adverse motor effects induced by antiepileptic drugs","volume":"6","author":"Zaccara","year":"2004","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2015.07.004_bib0535","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0540","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","article-title":"Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies","volume":"17","author":"Zaccara","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2015.07.004_bib0545","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00228-014-1669-y","article-title":"Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective","volume":"70","author":"Zaccara","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0550","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/ene.12170","article-title":"The adverse event profile of perampanel: meta-analysis of randomized controlled trials","volume":"20","author":"Zaccara","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0555","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00228-012-1213-x","article-title":"The adverse event profile of pregabalin across different disorders: a meta-analysis","volume":"68","author":"Zaccara","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2015.07.004_bib0560","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.004_bib0565","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.pmrj.2010.04.018","article-title":"Mechanisms by which pharmacologic agents may contribute to fatigue","volume":"2","author":"Zlott","year":"2010","journal-title":"PM R"},{"key":"10.1016\/j.seizure.2015.07.004_bib0570","unstructured":"Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. http:\/\/tech.cochrane.org\/revman\/about-revman-5."}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131115001673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131115001673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:45:36Z","timestamp":1761011136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131115001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":57,"alternative-id":["S1059131115001673"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2015.07.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adverse event profile of levetiracetam: A meta-analysis on children and adults","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2015.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}